New Delhi: Akums Drugs and Pharmaceuticals Limited announces the launch rabeprazole , Levosulpiride SR CapsulesThis new formulation, approved by the Drugs Controller General of India (DCGI), aims to provide relief to patients suffering from asthma. Gastrointestinal Gastrointestinal tract (GIT) disorders.

GERDGastro-oesophageal reflux disease, or gastro-oesophageal reflux disease, is a debilitating condition that involves stomach contents coming back up into the oesophagus, causing bothersome symptoms and potential complications. GERD is often referred to as chronic Acid refluxIts long-term presence not only affects quality of life but also poses a risk of serious health complications, including stomach and esophageal cancer.

Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase on the surface of gastric parietal cells. It has demonstrated efficacy in the treatment of gastric and duodenal ulcers as well as GERD. As a complement to rabeprazole, levosulpiride, the levo-enantiomer of sulpiride, exhibits significant central antidopaminergic activity and antiemetic effects. Its peripheral anti-dopaminergic action modulates the motor activity of the upper digestive tract, making it valuable in gastro-enterology.

Arushi Jain, Director, Akams Drugs & Pharmaceuticals Ltd. commented, “We are excited to offer a solution for patients suffering from GERD and related gastrointestinal disorders. The diagnosis and treatment of GERD depends on symptom management and acid suppression therapy. Our Rabeprazole + Levosulpiride SR Capsule aims to provide an effective remedy, alleviating symptoms, enhancing gastrointestinal function and promoting the overall well-being of patients. Levosulpiride provides faster relief and better treatment outcomes with fewer side effects, improving the overall treatment experience.”

Sandeep Jain, Managing Director, Akms Drugs & Pharmaceuticals Ltd, said, “The first step to treating any disease is awareness. Increasing awareness about GERD is important to reduce the risk of developing this condition. We hope that this formulation will bring a meaningful change in the lives of patients. I must appreciate the efforts of our R&D team who have helped bring out this formulation.”

Each hard gelatin capsule contains rabeprazole sodium i.p. 40 mg (as enteric-coated form) and levosulpiride 75 mg (as uncoated sustained-release form). The recommended dosage is one capsule once daily or as directed by a physician.